JAK Inhibitors and Pathophysiology of Atopic Dermatitis

Author(s):

Raj Chovatiya, MD, PhDGeorge Han, MD, PhD

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

Now Viewing

EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis

EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis

EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients

EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice

EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis

EP: 7.Speed of Itch Relief in Atopic Dermatitis

EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis

EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis

EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

Video content above is prompted by the following:

Please provide a brief overview of the pathophysiology of atopic dermatitis (AD), a chronic inflammatory condition.

How do JAK inhibitors contribute to the pathophysiology of AD?